* Study results confirms that its BI 695501 and Humira have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis

* Boehringer Ingelheim presents Phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to Humira

* Boehringer Ingelheim - co-primary endpoints at weeks 12 and 24 were met in the Phase III study Source text for Eikon: